DNB Bioteknologi
DNB Bioteknologi is an equity fund which primarily invests in shares listed on stock exchanges and regulated markets across the world.
Actively managed equity fund
Invests in vaccines, medicines and diagnostics
On your mobile phone, you buy DNB Biotechnology in The Spare app
You can buy DNB Bioteknologi using a computer or in the Spare app
DNB Bioteknologi
The fund mainly invests in the following sectors:
- Biotechnology
- Diagnostics
- Pharmacy
- Production of pharmaceutical products
- Biological medicines including gene therapy
- Other health-related businesses
Minimum purchase amount is NOK 100. With a savings scheme in mutual funds, your savings happen automatically every month.
Costs for DNB Biotechnology A
- Annual cost 1.15%
- Ongoing charge: 0.85%
- Platform fee 0.30%
Price example: For an amount of NOK 100,000 invested, the platform fee will be NOK 300 and ongoing costs will amount to NOK 850 over the course of one year. A total of NOK 1150 per year.
Any transaction costs to the Portfolio Manager are not included in the cost overview. These are given under cost details on the summary page before you buy the mutual fund.
DNB Biotechnology management team
The health funds in DNB Asset Management are managed by a team with extensive experience in medicine and finance, consisting of:
- Benedicte Kilander Bakke
- Rune Sand
- Anesa Mulabecirovic Sahnoun
Benedicte is a qualified dentist in addition to being an authorised financial analyst (AFA) with an MBA in Finance, Rune has a master’s degree in Finance and also an AFA and an MBA in Finance, and Anesa is a medic with a doctorate in medicine and also has an MBA in Finance.
Are you looking for advisory services?
Find out which type of investment is right for you. Our advisers will do a review of your overall finances and what you want to get from your savings.
The Spare app
The Spare app brings all your savings together in one place and gives you a full overview of your investments.
Historical returns are no guarantee of future returns. Future returns will depend, among other things, on market developments, the skill of the Portfolio Manager, the mutual fund’s risk, and the management costs. Returns may be negative as a result of mark-to-market losses.
See more mutual funds here
See all our mutual funds
See our full range of mutual funds here
Digital adviser
Get customised research and investment suggestions adapted to you.
DNB Nordisk Utbytte
Invests mainly in companies that pay dividends
DNB European Defence
Invests in companies that are relevant to the overall defence system
DNB Kjernekraft
Invests in companies involved in the nuclear sector
DNB Global Enhanced Small CAP
Invests in small and medium-sized companies in advanced economies (IMF)
DNB Fund Disruptive Opportunities
Invests in companies that operate in pioneering technologies
DNB Fund Nordic Small Cap
Invests in smaller, publicly-listed Nordic companies
DNB Norge
Invests mainly in Nordic securities on the Oslo Stock Exchange
DNB SMB
Invests in small and medium-sized businesses, mainly in Norway
DNB Bioteknologi
Invests in vaccines, medicines and diagnostics
DNB Health Care
Equity fund that invests in healthcare companies globally
DNB Finans
Invests in the financial sector and other related businesses
DNB Global Emerging Markets
Invests in developing markets across the world
DNB Global
Normal breadth of exposure across regions and sectors
DNB Teknologi
Broad exposure to the digital companies in the world
DNB Global Indeks
Invests in companies listed on stock exchanges in developing economies